Cognition Therapeutics Inc (CGTX) ニュース

CGTX...........................https://stockcharts.com/h-sc/ui?s=CGTX&p=W&b=5&g=0&id=p86431144783

.69 still going 34m float watch .76 resistance probably max gain. But if it breaks it .90 possible 

Flip rest at .5970

DILUTE INTO FLUFF NEWS

.58 flipping half from .47 

.53 “We now have evidence that the dramatic reduction of cognitive decline that was sustained over 6 months in patients treated with CT1812 who had lower plasma p-tau217 levels also was associated with improvements in key indicators of brain cell function. This finding gives us confidence that CT1812 is having a disease-modifying effect,” explained Anthony O. Caggiano, MD, PhD, Cognition’s C

.47 . - Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -

More attention here is on the way, imo.

I’m in

CGTX new 52. Week low

T1 halt….

No news
https://ih.advfn.com/markets/nasdaq/premarket

CGTX under $3

Whoops, I did it, again

CGTX under $2

Great stock. Future is bright. Bags packed.

CGTX under $2

CGTX under $2

CGTX under $2

CGTX new 52 week low

CGTX under $2

Is that a wild guess or is there some reasoning behind your statement?

Time to buy.

Great! I believe we'll do quite well on share price surge!

Already been here for a few weeks …lol. One of my very few longer term hold OTC plays.
Thanks..

Nice "pop" on FDA phase II news! If you have time, you may want to check out GDVM. Symbol change happening any day. Two hours of reading you'll be buying shares.

The START study is supported by a grant of approximately $81 million for 5 years from the National Institutes of Health’s (NIH) National Institute on Aging (NIA) to accelerate development of new therapies for Alzheimer’s disease.

“The START study and ACTC represent some of the many ways that NIA funds research into novel therapeutics for treating Alzheimer's and related dementias,” stated Laurie Ryan, Ph.D., an NIA clinical research program official.

“We appreciate the continued support of the NIA, which has been an important partner in our work to develop CT1812. Our lead drug candidate is a potentially disease-modifying oral therapeutic for the treatment of Alzheimer's disease and other neurodegenerative conditions,” added Cognition president and CEO, Lisa Ricciardi. “With the NIA's funding, we have been able to complete a series of preclinical and clinical trials, thus advancing our understanding of CT1812 and the role of the sigma-2 (s-2) receptor in Alzheimer’s disease. We look forward to recruiting patients for the START study with our collaboration partners at the ACTC.”

“ACTC aims to accelerate Alzheimer’s drug development, working with academic and industry partners,” said Paul Aisen, M.D., professor of neurology at the University of Southern California and director of the Alzheimer's Therapeutic Research Institute. “The START study is an important component of ACTC efforts. Having an authorized protocol for the START study is a critical step in preparing to open clinical sites for the trial by mid-2023.”

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease. This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consortium (ACTC). CT1812 is an investigational oral small molecule that binds to a receptor on synapses and is designed to prevent the toxic effects of soluble beta amyloid (Aß) oligomers on neurons, which drive the progression of neurodegenerative diseases such as Alzheimer’s disease.


“The initial clinical results observed with CT1812 are encouraging and we look forward to advancing it into the START trial to evaluate its effects in a larger study in people with early Alzheimer’s disease,” said Christopher H. van Dyck, M.D., director of the Yale Alzheimer's Disease Research Center and primary investigator of the START study. “We envision a future with multiple treatment options, to be used alone or in combination according to evidence, to achieve the greatest slowing of Alzheimer's disease progression.”

Chart is looking better all of the time. The 50 day MA is only about 15 cents away from the 200 day and when we get the golden cross that should trigger a lot of buy signals.

$CGTX Love the chart..looking for continuation next week..

https://stockcharts.com/c-sc/sc?s=CGTX&p=D&b=5&g=0&i=0&r=1669471320227

Hopefully this has seen its low and now is starting a new uptrend. I just grabbed my first 1000 shares today after seeing the CEO added 71,000 shares.

Nope but not any major loss.

Were you able to get-out with a profit today?

While the stock is dropping on no relative news it is a good time to think about purchasing more shares. I have been averaging down and would not mind $2.00/share to bring me more in line with what makes me comfortable.

As a new investor in CGTX I look forward to new and interesting posts on the board. I am tired of plain B-S from those who get off on seeing there jibber in print.

Hope there is very little shorting done to this stock!!!!!

Hopefully we have a winner by end of this year.

I hope in the Mid 3's is a good starting point

As a new shareholder I fit the need going to be 77.

In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report), with a price target of $15.00. The company's shares closed last Thursday at $2.75, close to its 52-week low of $2.31. According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.4% and a 27.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. Cognition Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
https://www.tipranks.com/news/blurbs/b-riley-financial-thinks-cognition-therapeutics-stock-is-going-to-recover-5?utm_source=advfn.com&utm_medium=referral

Welcome to Cognition Therapeutics Inc (CGTX).